Title |
Evaluation of intravenous voriconazole in patients with compromised renal function
|
---|---|
Published in |
BMC Infectious Diseases, January 2013
|
DOI | 10.1186/1471-2334-13-14 |
Pubmed ID | |
Authors |
Craig M Lilly, Verna L Welch, Thomas Mayer, Paul Ranauro, Joanne Meisner, David R Luke |
Abstract |
Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Clcr) < 50 mL/min. This study evaluated the safety of IV voriconazole compared with two other IV antifungals not containing SBECD in patients with compromised renal function. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 20% |
Unknown | 4 | 80% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 1 | 20% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
Denmark | 1 | 3% |
Unknown | 38 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 20% |
Student > Ph. D. Student | 6 | 15% |
Other | 5 | 13% |
Student > Master | 5 | 13% |
Student > Postgraduate | 4 | 10% |
Other | 5 | 13% |
Unknown | 7 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 55% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 13% |
Business, Management and Accounting | 1 | 3% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Psychology | 1 | 3% |
Other | 1 | 3% |
Unknown | 9 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#12,868,348
of 22,693,205 outputs
Outputs from BMC Infectious Diseases
#2,976
of 7,644 outputs
Outputs of similar age
#154,618
of 284,977 outputs
Outputs of similar age from BMC Infectious Diseases
#51
of 166 outputs
Altmetric has tracked 22,693,205 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,644 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,977 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 166 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.